Skip to Content
Merck

Acute rhabdomyolysis associated with ofloxacin/levofloxacin therapy.

The Annals of pharmacotherapy (2004-11-25)
Shu-Hwa Hsiao, Chia-Ming Chang, Chao-Jung Tsao, Yu-Yun J Lee, May-Ying Hsu, Ta-Jen Wu
ABSTRACT

To report a case of ofloxacin/levofloxacin-induced rhabdomyolysis and to compare other reported cases from the literature. A 19-year-old male patient developed ofloxacin/levofloxacin-induced rhabdomyolysis during admission for periorbital cellulitis. Symptoms of myalgia, weakness, and swelling of the arms developed after 3 days of treatment with ofloxacin 800 mg/day. Laboratory analysis confirmed the presence of urine myoglobin (381.2 microg/L) and a marked increase in serum myoglobin (590.8 microg/L), along with marked elevations in serum creatine kinase (up to 16 546 IU/L). In addition to ruling out other possible etiologic factors one by one, we assessed the probability of ofloxacin/levofloxacin-induced rhabdomyolysis by observing the close time relationship between drug administration and the development of symptoms/signs, as well as the close time relationship between drug withdrawal and the disappearance of symptoms/signs. An objective causality assessment by use of the Naranjo probability scale revealed that the adverse drug reaction was probable. Although ofloxacin/levofloxacin-induced rhabdomyolysis appears to be rare, patients with muscle pain, swelling, or weakness during therapy should be closely monitored for this adverse effect.

MATERIALS
Product Number
Brand
Product Description

Supelco
Ofloxacin, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Ofloxacin, VETRANAL®, analytical standard
Sigma-Aldrich
Ofloxacin, fluoroquinolone antibiotic
Ofloxacin, European Pharmacopoeia (EP) Reference Standard